BeckerM. 2000. Oral cavity, oropharynx, and hypopharynx. Semin Roentgenol. 35(1):21–30.
2.
CooperJSPajakTFForastiereAAJacobsJCampbellBHSaxmanSBKishJAKimHECmelakAJRotmanM, et al. 2004. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 350(19):1937–1944.
3.
CorvòRBenassoMSanguinetiGLionettoRBacigalupoAMargarinoGPallestriniEMerlanoMVitaleVRossoR.2001. Alternating chemoradiotherapy versus partly accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck: results from a phase iii randomized trial. Cancer. 92(11):2856–2867.
4.
DenisFGaraudPBardetEAlfonsiMSireCGermainTBergerotPRheinBTortochauxJOudinotP, et al. 2003. Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int J Radiat Oncol Biol Phys. 55(1):93–98.
5.
FallaiCBolnerASignorMGavaAFranchinGPonticelliPTainoRRossiFArdizzoiaAOggionniM, et al. 2006. Long-term results of conventional radiotherapy versus accelerated hyperfractionated radiotherapy versus concomitant radiotherapy and chemotherapy in locoregionally advanced carcinoma of the oropharynx. Tumori. 92(1):41–54.
6.
HugueninPBeerKTAllalARufibachKFriedliCDavisJBPestalozziBSchmidSThöniAOzsahinM, et al. 2004. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol. 22(23):4665–4673.
7.
JeremicBShibamotoYMilicicBNikolicNDagovicAAleksandrovicJVaskovicZTadicL.2000. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol. 18(7):1458–1464.
8.
NabilSSammanN.2012. Risk factors for osteoradionecrosis after head and neck radiation: a systematic review. Oral Surg Oral Med Oral Pathol Oral Radiol. 113(1):54–69.
9.
RacadotSMercierMDussartSDessard-DianaBBensadounRJMartinMMalaurieEFavrelVHoussetMDurduxC, et al. 2008. Randomized clinical trial of post-operative radiotherapy versus concomitant carboplatin and radiotherapy for head and neck cancers with lymph node involvement. Radiother Oncol. 87(2):164–172.
10.
SaenthaveesukPKiat-AmnuaySWaljiMF. 2022. Using electronic dental records to assess osteoradionecrosis risk in irradiated head and neck cancer. JDR Clin Trans Res. 8(3):244–256.
11.
SemrauRMuellerRPStuetzerHStaarSSchroederUGuntinas-LichiusOKocherMEichHTDietzAFlentjeM, et al. 2006. Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5-fluorouracil: updated results of a randomized multicentric trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 64(5):1308–1316.
12.
SkladowskiKMaciejewskiBGolenMTarnawskiRSlosarekKSuwinskiRSygulaMWygodaA.2006. Continuous accelerated 7-days-a-week radiotherapy for head-and-neck cancer: long-term results of phase iii clinical trial. Int J Radiat Oncol Biol Phys. 66(3):706–713.
13.
TrottiAPajakTFGwedeCKPaulusRCooperJForastiereARidgeJAWatkins-BrunerDGardenASAngKK, et al. 2007. Tame: development of a new method for summarising adverse events of cancer treatment by the radiation therapy oncology group. Lancet Oncol. 8(7):613–624.
14.
ZanoniDKPatelSGShahJP. 2019. Changes in the 8th edition of the American Joint Committee on Cancer (AJCC) staging of head and neck cancer: rationale and implications. Curr Oncol Rep. 21(6):52.
